Geron Corporation — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; comparisons are with the three months ended March 31, 2011 unless otherwise noted. Geron was an early-stage biopharmaceutical company focused on oncology, with no marketed therapeutic products.
Business context and pipeline
Geron was evaluating imetelstat in four Phase 2 trials—metastatic breast cancer, advanced non-small cell lung cancer (NSCLC), essential thrombocythemia and multiple myeloma—and GRN1005 in two Phase 2 trials for brain metastases associated with breast cancer and NSCLC. The company had discontinued further development of its stem-cell programs to focus on oncology and was seeking to divest those assets.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Total revenue | $1.254 million | $1.505 million |
| Research and development | $15.107 million | $16.755 million |
| General and administrative | $5.065 million | $9.106 million |
| Operating loss | $18.918 million | $24.356 million |
| Net loss | $18.739 million | $24.389 million |
| Basic and diluted loss per share | $0.15 | $0.20 |
| Net cash used in operations | $16.585 million | $12.708 million |
Revenue comprised $861,000 of royalties and $393,000 of license fees; there was no collaborative-agreement revenue in Q1 2012. Royalties related to research-use products and nutritional products, rather than therapeutic drug sales. The filing does not provide a meaningful gross-margin measure for these activities.
At March 31, 2012, cash and cash equivalents were $19.0 million, marketable securities were $117.1 million and restricted cash was $0.8 million, or approximately $136.9 million combined. Total current assets were $122.5 million and current liabilities were $10.3 million. Stockholders’ equity was $130.9 million; accumulated deficit was $804.2 million. The balance sheet reported no conventional borrowings; approximately $500,000 remained available under the equipment financing facility. Q1 investing cash flow was positive $19.5 million, mainly reflecting maturities of marketable securities; financing cash flow was zero.
Changes versus prior period and unusual items
- Net loss narrowed by $5.7 million, chiefly due to reduced R&D spending following the stem-cell program shutdown and lower non-cash stock-based compensation.
- R&D expense fell $1.6 million overall: lower personnel and scientific-supply costs were partly offset by higher clinical-trial and drug-manufacturing costs. Oncology R&D rose to $13.3 million from $9.2 million; hESC-therapy R&D fell to $1.8 million from $7.6 million.
- G&A expense declined $4.0 million, primarily because Q1 2011 included $3.5 million of additional non-cash compensation related to the former CEO’s separation.
- Operating cash use increased $3.9 million, primarily reflecting restructuring payments and less use of stock to pay for services.
- Restructuring accrual declined to $1.4 million from $3.7 million after $2.3 million of cash payments. Additional charges could arise from exiting leased space; equipment-sale proceeds might offset some costs.
- The GE Healthcare alliance had concluded in June 2011, explaining the absence of related collaborative revenue in Q1 2012. No ViaGen equity-method loss was recorded in Q1 2012 because Geron had suspended that accounting in 2011; its investment carrying value was zero.
Outlook, risks and contingencies
Management estimated existing capital resources, interest income and equipment-facility availability would fund the current operating level through at least the next 12 months. It also cautioned that future capital needs would be substantial and that additional financing might not be available on acceptable terms. Management expected R&D expense to remain around current levels as the oncology trials continued.
Management expected top-line data from the imetelstat Phase 2 trials by the end of 2012 and from the GRN1005 trials by the end of Q2 2013. Enrollment in the imetelstat multiple-myeloma and essential-thrombocythemia trials was slower than expected; GRN1005 enrollment goals were described as aggressive. No formal earnings or revenue guidance was provided.
Key disclosed risks include clinical-trial failure or delay, safety issues, drug-supply and manufacturing scale/cost challenges, reliance on third-party vendors, regulatory uncertainty, patent disputes, and the need for future financing. Prior trials observed dose-limiting toxicities for both candidates. Geron also noted that stem-cell divestiture proceeds, if any, were uncertain. No legal proceedings were reported, although the filing describes ongoing patent opposition matters. The company reported no off-balance-sheet arrangements and stated that disclosure controls were effective at a reasonable-assurance level.
Important facts for investors to verify
- Whether Phase 2 enrollment, safety and efficacy results supported the stated data timelines, especially given slower enrollment in two imetelstat trials.
- Whether the estimated 12-month funding runway held up against operating cash use and the cost of ongoing trials and manufacturing.
- Whether Geron completed a stem-cell asset divestiture and received meaningful proceeds, and whether facility-exit charges arose.
- Whether imetelstat and GRN1005 manufacturing could meet later-stage quality, capacity and cost requirements, including the disclosed single-source supply risks.
- Whether additional capital was required and, if so, the impact of financing terms and potential dilution; shareholders were being asked to approve an increase in authorized common shares from 200 million to 300 million.